Fortrea has inked a deal with Australia’s Incannex Healthcare to manage investigative new drug clinical trials for a cannabinoid-based treatment for obstructive sleep apnea.

Fortrea已经与澳大利亚的Incannex医疗保健公司签订了一份协议，负责管理基于大麻素治疗阻塞性睡眠呼吸暂停的新药临床试验研究。

The phase 2 and phase 3 trials will be designed to assess Incannex’s IHL-42X, a low dose of the anti-nausea drug dronabinol, a synthetic form of tetrahydrocannabinol, and the diuretic acetazolamide.

第2阶段和第3阶段试验将设计用于评估Incannex的IHL-42X，低剂量的抗恶心药物屈大麻酚，合成形式的四氢大麻酚和利尿剂乙酰唑胺。

A fairly common condition, obstructive sleep apnea causes the walls of the throat to relax and narrow during sleep, interrupting normal breathing that can lead to regularly interrupted sleep. In more severe cases, the condition can temporarily stop breathing during sleep.

阻塞性睡眠呼吸暂停是一种相当常见的疾病，在睡眠过程中会导致喉咙壁松弛并变窄，从而中断正常呼吸，从而导致睡眠定期中断。在更严重的情况下，该病症可以在睡眠期间暂时停止呼吸。

Fortrea—the CRO spinoff from Labcorp—was previously engaged in a 12-week operational feasibility study of the trial that was provided to potential investigators to gauge their interest, the company said in a July 18 press release. While 63 sites said they were interested, Incannex is targeting 45 for the study..

Fortrea该公司在7月18日的新闻稿中表示，Labcorp的CRO分拆之前曾参与该试验的12周运行可行性研究，该研究提供给潜在的研究人员以衡量他们的兴趣。虽然有63个网站表示有兴趣，但Incannex的目标是45个网站。。

“Fortrea’s familiarity with the study and established relationships with potential trial sites will expedite the study start-up and site engagement activities,” Joel Latham, Incannex chief executive and managing director, said in the release.

INCANEX首席执行官兼总经理Joel Latham在该版本中说：“Fortrea熟悉这项研究并与潜在试验场所建立关系将加快研究启动和现场参与活动。

Labcorp announced plans last July to spin off its CRO operations into an independent, publicly traded company dubbed Fortrea. While under the Labcorp umbrella, the division reaped $3 billion in revenue in 2022, accounting for between 15% to 20% of Labcorp’s central lab business.

Labcorp去年7月宣布计划将其CRO业务分离为一家名为Fortrea的独立上市公司。在Labcorp的保护下，该部门于2022年获得30亿美元的收入，占Labcorp中央实验室业务的15%至20%。